
    
      Phase II, Open, prospective, not controlled, not randomized clinical trial in patients
      affected by post-traumatic syringomyelia. The trial evaluates the efficacy of the cell
      therapy NC1 administered via intrathecal in the location of the injury. After the
      administration of the cell therapy, patients will undergo physiotherapy during the follow-up
      period (6 months). Patients will be evaluated at month 3 and month 6 after the NC1
      administration.
    
  